Cantemir Alina, Alexa Anisia I, Anton Nicoleta, Ciuntu Roxana E, Danielescu Ciprian, Chiselita Dorin, Costin Danut
"Grigore T. Popa" University of Medicine and Pharmacy, Iasi, Romania.
Ophthalmol Ther. 2017 Jun;6(1):147-160. doi: 10.1007/s40123-017-0076-8. Epub 2017 Feb 3.
The purpose of this study was to evaluate the efficacy and safety of iontophoretic collagen cross-linking (I-CXL) compared to epithelium-off standard collagen cross-linking (CXL) in treating the early stages of progressive keratoconus.
This retrospective cohort study at Oftaprof Clinic, Iasi, Romania included 40 eyes of 40 patients with progressive keratoconus stage I according to the Amsler classification who underwent I-CXL and the results were compared with a matched group of 40 eyes from 40 patients who received standard CXL. The follow-up period was 24 months. Uncorrected (UCVA) and corrected (CDVA) distance visual acuities, corneal topography, and pachymetry were evaluated in all patients.
The mean patient age was 26.52 ± 3.77 years for the standard CXL group and 28.32 ± 4.91 for the I-CXL group. The mean UCVA and CDVA improved significantly in both groups. At 12 months, the improvement of UCVA was greater in the I-CXL group (P < 0.05). There was a statistically significant different trend in CDVA between groups with a more favorable outcome for the standard CXL group (P < 0.01). The manifest cylinder decreased by a mean of 0.962 ± 0.114 D in the epithelium-off CXL group and by 0.831 ± 0.082 D in the I-CXL group (P < 0.001). At 24 months, the K values improved by 1.2 ± 0.199 D in the standard group and by 0.908 ± 0.177 D in the I-CXL group (P < 0.001).
All parameters either improved or remained unchanged after the iontophoretic collagen cross-linking intervention. I-CXL was found to be as effective as the standard technique.
本研究旨在评估离子导入胶原交联术(I-CXL)与去上皮标准胶原交联术(CXL)相比,在治疗早期进行性圆锥角膜中的疗效和安全性。
在罗马尼亚雅西的奥夫塔罗夫诊所进行的这项回顾性队列研究,纳入了40例根据阿姆斯勒分类法处于I期进行性圆锥角膜的患者的40只眼,这些患者接受了I-CXL,并将结果与40例接受标准CXL的患者的40只眼的匹配组进行比较。随访期为24个月。对所有患者评估未矫正(UCVA)和矫正(CDVA)远视力、角膜地形图和角膜厚度测量。
标准CXL组患者的平均年龄为26.52±3.77岁,I-CXL组为28.32±4.91岁。两组的平均UCVA和CDVA均显著改善。在12个月时,I-CXL组的UCVA改善更大(P<0.05)。两组之间CDVA存在统计学上的显著差异趋势,标准CXL组的结果更有利(P<0.01)。去上皮CXL组的明显柱镜度数平均降低0.962±0.114D,I-CXL组降低0.831±0.082D(P<0.001)。在24个月时,标准组的K值改善了1.2±0.199D,I-CXL组改善了0.908±0.177D(P<0.001)。
离子导入胶原交联干预后,所有参数均有所改善或保持不变。发现I-CXL与标准技术一样有效。